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A B S T R A C T
The pharmacokinetics and neurotoxicity of paraquat dichloride (PQ) were assessed following once
weekly administration to C57BL/6J male mice by intraperitoneal injection for 1, 2 or 3 weeks at doses of
10, 15 or 25 mg/kg/week. Approximately 0.3% of the administered dose was taken up by the brain and
was slowly eliminated, with a half-life of approximately 3 weeks. PQ did not alter the concentration of
dopamine (DA), homovanillic acid (HVA) or 3,4-dihydroxyphenylacetic acid (DOPAC), or increase
dopamine turnover in the striatum. There was inconsistent stereological evidence of a loss of DA
neurons, as identiﬁed by chromogenic or ﬂuorescent-tagged antibodies to tyrosine hydroxylase in the
substantia nigra pars compacta (SNpc). There was no evidence that PQ induced neuronal degeneration in
the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of
silver stain or reduced immunolabeling of tyrosine-hydroxylase-positive (TH+) neurons. There was no
evidence of apoptotic cell death, which was evaluated using TUNEL or caspase 3 assays. Microglia (IBA-1
immunoreactivity) and astrocytes (GFAP immunoreactivity) were not activated in PQ-treated mice 4, 8,
16, 24, 48, 96 or 168 h after 1, 2 or 3 doses of PQ.
In contrast, mice dosed with the positive control substance, 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP; 10 mg/kg/dose  4 doses, 2 h apart), displayed signiﬁcantly reduced DA and DOPAC
concentrations and increased DA turnover in the striatum 7 days after dosing. The number of TH+
neurons in the SNpc was reduced, and there were increased numbers of degenerating neurons and
neuronal processes in the SNpc and striatum. MPTP-mediated cell death was not attributed to apoptosis.
MPTP activated microglia and astrocytes within 4 h of the last dose, reaching a peak within 48 h. The
microglial response ended by 96 h in the SNpc, but the astrocytic response continued through 168 h in
the striatum.
These results bring into question previous published stereological studies that report loss of TH+
neurons in the SNpc of PQ-treated mice. This study also suggests that even if the reduction in TH+
neurons reported by others occurs in PQ-treated mice, this apparent phenotypic change is
unaccompanied by neuronal cell death or by modiﬁcation of dopamine levels in the striatum.
 2013 Elsevier Inc. 
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Paraquat (1,10-dimethyl-4,40-bipyridinium dichloride, [PQ]) is a
non-selective herbicide that interferes with photosynthesis
(photosystem I) and damages plant membrane proteins by the
production of oxygen free radicals. PQ is used pre-planting or pre-
emergence on a variety of crops, and post-emergence around fruit
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Although occupational exposure to PQ occurs mainly by the dermal
route, PQ is poorly absorbed through intact human skin (0.03 mg/
cm2 over 24 h), with only 0.3% of the applied dose absorbed
within 24 h (Wester et al., 1984).
The association between pesticide use, rural living or living on a
farm and the occurrence of Parkinson’s disease (PD) has been
reviewed (Wirdefeldt et al., 2011) and evaluated in several meta-
analyses (Priyadarshi et al., 2000; Brown et al., 2006; Van der Mark
et al., 2012) but reports of an association between PQ use and PD
(Liou et al., 1997; Tanner et al., 2011) have been questioned (Berry
et al., 2010; Mandel et al., 2012; Van Maele-Fabry et al., 2012). In
addition, although PQ is frequently stated to be a structural analog
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a chem-
ical frequently used as an animal model of PD (Jackson-Lewis and
Smeyne, 2005; Jackson-Lewis et al., 1995, 2012; Jackson-Lewis and
Przedborski, 2007), there is doubt that the reported effect of PQ on
dopaminergic neurons could be mediated by the same mechanism
as described for 1-methyl-4-phenylpyridinium (MPP+), the active
metabolite of MPTP (Miller, 2007; Richardson et al., 2007;
Ramachandiran et al., 2007).
When PQ was administered by intraperitoneal (ip) injection to
male C57BL/6J mice, a reduction in the number of tyrosine-
hydroxylase-positive (TH+) neurons in the substantia nigra pars
compacta (SNpc) has been reported (Brooks et al., 1999;
McCormack et al., 2002; Jiao et al., 2012). However, because
the detection of dopaminergic neurons depends on TH+ immuno-
reactivity, a reduction in the number of TH+ neurons is not
conclusive evidence that dopaminergic neurons have actually died.
Although some authors have reported that the total number of
neurons in the SNpc was reduced concomitantly with the
reduction in the number of TH+ neurons in Nissl-counterstained
sections (McCormack et al., 2002), few investigators have assessed
the effect of PQ on total neuronal count in the SNpc using Nissl-
only stain. Furthermore, because the reduction in the number of
TH+ neurons has been reported to occur only after the second or
third ip injection of PQ, but not after the ﬁrst injection (McCormack
et al., 2005), it is important to consider the timing of dose and the
number of doses administered when assessing effects of PQ on the
SNpc.
There is limited supporting evidence (McCormack et al., 2002,
2006; Purisai et al., 2007; Mitra et al., 2011) and some
contradictory evidence (McIntosh et al., 2010) that dopaminergic
neurons die following either PQ (McCormack et al., 2002, 2006) or
PQ plus maneb (McIntosh et al., 2010) treatment, as indicated by
the uptake of amino cupric silver stain and the activation of
microglia and astrocytes in response to the appearance of dying
and degenerating neurons. In one study, it was suggested that an
observed reduction in TH+ neurons in the SNpc in mice
administered 10 doses of PQ (7 mg/kg/dose) over a 20-day period
was due to cell death by an apoptotic mechanism (Peng et al.,
2004).
The concentrations of dopamine (DA) and its metabolites 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA),
as well as DA turnover in the striatum of C57BL/6J mice, have been
reported to be either unaffected (Woolley et al., 1989) or only
marginally affected by PQ treatment (McCormack et al., 2002,
2005). Others have reported reductions in DA levels (Kang et al.,
2009) and/or increases in DA turnover (Shepherd et al., 2006;
Songin et al., 2011) in adult mice when the animals were exposed
to PQ prenatally (Barlow et al., 2004), or when PQ was
administered daily for 24 days prior to an evaluation which
occurred 7 days after the last dose (Prasad et al., 2009).
There is indirect evidence that PQ may be transported across
the blood–brain barrier via the neutral amino acid transporter
(Shimizu et al., 2001; McCormack & Di Monte, 2003) or the organiccation transporters, OCT-2 and OCT-3 (Chen et al., 2007; Rappold
et al., 2011). While it has been postulated that PQ is taken up into
dopaminergic neurons by the dopamine transporter (DAT), the
divalent paraquat cation does not appear to be a substrate for DAT
(Foster et al., 2004; Richardson et al., 2005). Recent studies have
suggested that the paraquat monovalent cation, which could form
in a reduced anoxic environment, is transported into dopamine
neuron terminals by DAT (Rappold et al., 2011) in a manner
analogous to the transport of MPP+ (Cui et al., 2009). However,
direct measurement of [14C] PQ in the brain has consistently shown
low-level, homogenous labeling with no evidence of tissue
localization, except in pigmented structures (Lindquist et al.,
1988) or in structures outside the blood–brain barrier, such as the
olfactory bulb and the tissues lining the lateral ventricles of the
brain (Lindquist et al., 1988; Widdowson et al., 1996).
The pharmacokinetics of PQ in plasma and the brain have been
described for male C57BL/6J mice (Prasad et al., 2007, 2009), the
animal model that is most frequently used to assess the effect of PQ
on dopaminergic neurons (McCormack et al., 2002). Prasad et al.
(2009) reported that it took approximately 18 days of PQ treatment
to reach a steady-state concentration in the frontal cortex, striatum,
hippocampus and cerebellum of male C57BL/6J mice, and that PQ
was slowly eliminated from the brain after the last dose.
The present series of studies were conducted to further
investigate the mechanisms of action underlying the reported
neurochemical and stereological effects of 1, 2 or 3 ip doses of
10 mg PQ/kg/occasion. Initial ﬁndings failed to conﬁrm stereologi-
cal results reported in the literature. In order to understand the
basis for this, the potential dose-response was evaluated using an
intermediate (15 mg PQ/kg/occasion) and a maximum-tolerated
dose (25 mg PQ/kg/occasion) in young adult male C57BL/6J mice.
In addition, the effects of highly-puriﬁed, analytical-grade PQ
(supplied by Syngenta) were compared to the effects of PQ
obtained from Sigma–Aldrich, a source of PQ commonly used by
other investigators. Histopathological correlates of the reported
loss of TH+ stained dopaminergic neurons and neuronal processes
in the SNpc and striatum were evaluated by conducting detailed,
blinded, intensive time-series evaluation of indicators of cellular
necrosis, apoptosis and glial activation in the midbrain and
striatum. Pharmacokinetic parameters were determined in blood,
plasma and brain to relate any effect of PQ on stereological or
pathological endpoints to the concentration of PQ in the brain. A
relatively low dose of MPTP (10 mg/kg administered 4 times in a
single day with a 2 h inter-dose interval) was used as a positive
control throughout this series of studies to determine if the
methodology employed was sensitive enough to detect small
changes in the number of TH+ neurons in the SNpc.
2. Materials and methods
2.1. Study conduct
The in-life phase of studies reported herein were conducted in
the AAALAC-accredited (Association for Assessment and Accredi-
tation of Laboratory Animal Care International) laboratory of WIL
Research Laboratories, LLC. The pharmacokinetic study (Study 7)
was a non-GLP investigative study conducted at Syngenta’s Central
Toxicology Laboratory, UK. The other studies were conducted
according to Good Laboratories Practices Regulations (US EPA,
1989; OECD, 1997) and the protocols for these studies were
approved by the Institutional Animals Care and Use committee at
WIL Research Laboratories. Brain neurochemistry investigations
were performed by RTI International (Research Triangle Park, NC).
Microscopic slides of brain sections for pathology evaluation were
prepared by Neuroscience Associates Inc., Knoxville, TN and
examined by a pathologist (Tox Path Specialists, Frederick, MD)
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investigations were prepared and evaluated by a stereologist at
Experimental Pathology Laboratories (EPL, Sterling, VA) who was
blinded totreatmentgroup.AnalysesofPQionconcentrationinsamples
of brain tissue were conducted by Charles River Laboratories, UK.
2.2. Test article/dose preparation
The positive control substance, MPTP hydrochloride, a 100% pure
ﬁne white powder (Lot Number 128K1549), was obtained from
Sigma–Aldrich Inc., St. Louis, MO, and was stored at room
temperature. The test chemical, PQ dichloride, a coarse, light-gray-
to-white powder, was 99.9% pure and was supplied either by
Syngenta (Lot Number ASJ10083-03 [SYN PQ]) or by Sigma–Aldrich
(paraquat dichloride monohydrate, Lot Number SZE8163X [SIG PQ]).
PQ was stored with a desiccant at a temperature of 2–8 8C. The
vehicle control solution was 0.9% sodium chloride for injection, USP
(physiological saline; Lot Numbers C775940 and C783100, manu-
factured by Baxter Healthcare Corporation, Deerﬁeld, IL; and Lot
Numbers 75-179-DK, 76-255-DK, and 76-432-DK, manufactured by
Hospira Inc., Lake Forest, IL). All materials were used within the
period deﬁned by their respective expiration dates. Both MPTP and
PQ were formulated as solutions in 0.9% sodium chloride at
appropriate concentrations. All dose concentrations used throughout
these studies were veriﬁed by HPLC to be homogeneous, stable and
within  10% of the target concentration prior to dose administration.
2.3. Test animal/animal husbandry
Male C57BL/6J mice were supplied by the Jackson Laboratories,
Bar Harbor, ME. Each study utilized a single batch of animals
received at an approximate age of 6–7 weeks. Treatment with PQ
or vehicle commenced at approximately 9–10 weeks of age, and
MPTP administration occurred when the mice were approximatelyTable 1
Experimental design of studies conducted on PQ and MPTP.
Study Study title MPTP dosea PQ 
1 PQ dose tolerance NE 20, 
2 Neurochemistry studyg 10 mg//kg  4 10 m
3 Pathology: 1, 2, 4, or 7 days after last doseh 10 mg/kg  4 10 m
4 Stereology: 7 days after last doseg 10 mg/kg  4 SIG 
10 m
SYN
15 m
5 Stereology: 7 days after last doseh 10 mg/kg  4 10 m
15 m
25 m
6 Pathology: 4, 8, 16, 24, 48, 96 or 168 h after
last doseh
10 mg/kg  4 10 m
15 m
25 m
7 Pharmacokinetic: [14C] PQ concentration in blood,
plasma and brain 0.25, 0.5, 0.75, 1, 1.5, 4, 24,
72, 168 and 672 h after 1, 2 and 3 doses
NE Blo
1 or
Bra
1 or
or 3
a MPTP administered by ip injection 4 times/day (2 h inter-dose interval) for a total 
b Syngenta PQ or Sigma PQ (Study 4) administered by ip injection 1 time/day (7 day
c PQ concentration was measured in the forebrain, anterior to the striatum.
d Striatal dopamine, DOPAC, HVA and dopamine turnover.
e Number of TH+ neurons, Nissl-stained neurons and the total number on neurons d
f Cell death (cupric silver, TUNNEL, caspase 3), glial activation (IBA-1, GFAP), TH+ an
g Mice for stereology and/or neurochemistry killed by cervical dislocation and decapita
left and right striatum of male C57BL/6J mice administered either PQ or MPTP by ip in
h Mice for stereology and pathology killed by cardiac perfusion following anesthesia
NE, not evaluated; VC, vehicle control; PQ, paraquat; WT, wild type; KO, knock out; SY11–12 weeks of age. The mice were housed in individual, stainless-
steel, wire-mesh-ﬂoored cages. Food (PMI Nutrition International,
LLC Certiﬁed Rodent LabDiet1 5002) and the municipal water
supply were evaluated for potential contaminants.
During the 3–5 week quarantine period and subsequently, each
animal was observed twice daily for mortality, as well as for
changes in general appearance or behavior. At the end of the
quarantine period, the mice were randomly assigned to control and
treatment groups using a randomized block design, stratiﬁed by
weight. Individual body weight and food consumption were
recorded weekly for all animals beginning 2 weeks prior to the
initiation of vehicle, MPTP or PQ administration. A 12 h light–dark
photoperiod was maintained throughout each study; room
temperature and relative humidity were maintained at
22 8C  3 8C and 50%  20%, respectively.
2.4. Dose administration
PQ was administered by ip injection, either 1, 2 or 3 times, with
each dose separated by 1 week (Table 1). Doses evaluated in
Studies 1 through 7 included 1, 10, 15, 25, 30 or 35 mg PQ salt/kg/
occasion (Table 1). MPTP (expressed as free base) was adminis-
tered every 2 h by ip injection at a dose of 10 mg/kg/occasion with
a total of 4 doses being administered over an 8 h period. The dose
volume was 10 ml/kg. The vehicle control (VC) group was
administered 3 doses of vehicle, with each injection administered
1 week apart. The experimental designs for Studies 3 through 6 are
shown in Table 2.
2.5. Concentration of PQ in forebrain and neurotransmitter
concentrations in the striatum
Mice were euthanized by cervical dislocation, followed by
decapitation, 7 days after the last scheduled dose of either MPTP ordoseb PQ concc Neurochemd Stereologye Pathologyf
25, 30, 35 mg/kg  3 NE NE NE Lung, liver,
kidney
g/kg  3 NE Yes NE NE
g/kg  1 or 2 NE Yes NE Yes
vs. SYN PQ
g/kg  3
 PQ
g/kg  1, 2 or 3
Yes No Yes Yes
g/kg  3
g/kg  3
g/kg  3
No Yes Yes No
g/kg  1, 2 or 3
g/kg  1, 2 or 3
g/kg  1, 2 or 3
NE NE No Yes
od and plasma
 10 mg/kg  1 dose
in
 10 mg/kg/dose  1, 2
 doses
Yes NE NE NE
dose of 40 mg/kg/day.
 inter-dose interval) for a total of 1, 2 or 3 doses.
etermined in the SNpc.
d/Nissl staining in SNpc and striatum.
tion. DA, DOPAC, HVA and DA turnover evaluated in homogenates collected from the
jection according the to the dose regimen indicated.
 with sodium pentobarbital.
N, Syngenta, SIG, Sigma–Aldrich.
Table 2
Experimental design for Studies 3, 4, 5 and 6.
Study 3: number of mice/group in the combined neurochemistry, stereologya and pathology study
Group Treatmentb Neuropathology subsets Stereology
Subset Ac (24 h) Subset Bc (48 h) Subset Cc (96 h) Subset Dc (168 h) subset Ed (day 14)
1-VC Vehicle 5 5 5 5 5
2-Syn PQ (1  10) 5 5 5 5 5
3-Syn PQ (2  10) 5 5 5 5 5
4-Sig MPTP (4  10) 5 5 5 5 5
Study 4: number of mice/group in the combined brain PQ, stereology and pathology study
Group Treatmentb Neuropathology subsets Stereology
Subset Ac (24 h) Subset Bc (48 h) Subset Cc (96 h) Subset Dc (168 h) subset Ed (day 14)
1-VC Vehicle 5 5 5 5 10
2-Syn PQ (3  10) 5 5 5 5 10
3-Syn PQ (3  15) 0 5 0 5 10
4-Syn PQ (2  15) 0 5 0 5 10
5-Syn PQ (1  15) 0 5 0 5 10
6-Sig PQ (3  10) 5 5 5 5 10
7-Sig MPTP (4  10) 0 5 0 5 10
Study 5: number of mice/group in the combined neurochemistry and stereology study
Group Treatmentb Stereologyd chromogenic Stereologyd ﬂuorescent Neurochemistryd
1-VC Vehicle 10 10 10
2-Syn PQ (10  3) 10 10 10
3-Syn PQ (15  3) 10 10 10
4-Syn PQ (25  3) 10 10 10
5-Sig MPTP (10  4) 10 10 10
Study 6: number of mice/group in the pathology study
Group Treatmentb Subset A 4 h Subset B 8 h Subset C 16 h Subset D 24 h Subset E 48 h Subset F 96 h Subset G 168 h
1-VC Vehicle 5 5 5 5 5 5 5
2-Syn PQ (1  10) 5 5 5 5 5 5 5
3-Syn PQ (1  15) 5 5 5 5 5 5 5
4-Syn PQ (1  25) 5 5 5 5 5 5 5
5-Syn PQ (2  10) 5 5 5 5 5 5 5
6-Syn PQ (2  15) 5 5 5 5 5 5 5
7-Syn PQ (2  25) 5 5 5 5 5 5 5
8-Syn PQ (3  10) 5 5 5 5 5 5 5
9-Syn PQ (3  15) 5 5 5 5 5 5 5
10-Syn PQ (3  25) 5 5 5 5 5 5 5
11-Sig MPTP (10  4) 5 5 5 5 5 5 5
a Tissues collected but the slides were inadequate to conduct stereology.
b Mice were administered either 2 (Study 3) or 3 doses (Studies 4–6) of the vehicle at a dose volume of 10 ml/kg or 1, 2 or 3 doses of 10, 15 or 25 mg PQ/kg/dose or 4 doses of
MPTP on a single day at a dose of 10 mg/kg MPTP/dose (Total MPTP dose = 40 mg/kg).
c Mice were killed either 4, 8, 16, 24, 48, 96 or 168 h after the last dose of either PQ or MPTP.
d Mice were killed 7 days after the last dose of PQ or MPTP for stereology, neurochemistry (Studies 3 and 5) and brain chemistry (Study 4).
VC, vehicle control; PQ, paraquat; WT, wild type; KO, knock out; SYN, Syngenta, SIG, Sigma–Aldrich.
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the forebrain (Study 4), the brain of each mouse was rapidly
removed, placed in a mouse brain matrix, and a coronal block of
tissue section rostral to the striatum was collected, weighed and
then immediately ﬂash-frozen in liquid nitrogen and stored frozen
(at approximately 70 8C) until shipment to Charles River
Laboratories, UK. The PQ concentration in the forebrain was
determined by LC-MS-MS method (Charles River’s Analytical
Method Number 8936, version 2; limit of quantiﬁcation
[LOQ] = 0.5 ng PQ ion/g).
Brain samples collected for neurochemistry (Studies 2, 3 and 5)
were obtained from the rostral to the caudal extent of the striatum.
Concentrations of DA, DOPAC and HVA were measured via HPLC by
injecting a 20-mL aliquot of the homogenate supernatant onto a
Zorbax SB-C18, 4.6 mm  250 mm column coupled to a Waters 464
Electrochemical Detector (time constant: 0.1 s; cell potential:
800 mV; cell current: 10 nA). The striatal concentration of each
analyte was determined by comparing the area of each peak to the
corresponding neurotransmitter peak area obtained from a standard
curve. Dopamine turnover was calculated ([DOPAC + HVA]/DA]).2.6. Pharmacokinetic study of PQ in blood, plasma and brain
Study 7 was conducted to characterize the uptake and
clearance of [14C]-paraquat ion ([14C] PQ) from whole blood,
plasma and brain of male C57BL/6J mice administered 1, 2 or 3
doses of 1 or 10 mg PQ/kg on days 0, 7 or 14 (Fig. 1B). [14C] PQ was
used because it had previously been established that PQ is not
metabolized to a signiﬁcant extent in rodents (Macpherson,
1995; JMPR, 2003). Blood/plasma samples were collected in
heparinized tubes from groups of mice (N = 3) by cardiac
puncture following anesthesia with isoﬂurane, from 0.25, 0.5,
0.75, 1, 1.5, 4, 24, 72, 168 or 672 h after a single dose of PQ
(Fig. 1C). Brains from either perfused or non-perfused animals
were dissected into 4 compartments (olfactory lobes, forebrain,
midbrain and cerebellum), weighed and analyzed. Samples were
oxidized (combustion efﬁciency ranged from 90.9 to 110%), and
the 14CO2 generated was absorbed and mixed with the
scintillation cocktail, and then analyzed in a calibrated liquid
scintillation counter (Packard Tricarb system). The number of
disintegrations per minute (dpm) was calculated after correction
Fig. 1. Pharmacokinetics of [14C] paraquat in the blood, plasma and brain of male C57BL/6J mice administered an ip dose of 1 or 10 mg/kg weekly for 1 (panels A and C), 3
(panel B) or 23 weeks (panel D – PBPK model predictions; Study 7).
C.B. Breckenridge et al. / NeuroToxicology 37 (2013) 1–14 5for background and quenching. Paraquat ion concentration was
expressed as mg/g of tissue.
A preliminary physiologically based pharmacokinetic (PBPK)
model (not shown) was developed by The Hamner Institutes for
Health Sciences, Research Triangle Park, NC, based upon the
pharmacokinetic data obtained in Study 7, as well as on published
literature (e.g., Chui et al., 1988). The brain was described as two
compartments, with one compartment representing the structures
outside the blood–brain barrier (BBBo) and the other representing
structures inside the blood–brain barrier (BBBi), based on
differential kinetics between these two regions.
After ﬁtting the PBPK model to time-course data for blood,
plasma and brain (BBBo and BBBi) after 3 successive weekly ip
doses in mice at 1 and 10 mg/kg (Fig. 1B), the model was used to
estimate the terminal half-life in the BBBi. In classical pharmaco-
kinetics, (Gibaldi and Perrier, 2007) the dosing time to reach a
fraction of stable periodic behavior of a compound with repeated
dosing is expressed as Nt = 3.32  t1/2  log(1  fss) where N is
the number of doses, t is the interval between doses, t1/2 is the
terminal half-life and fss is the fraction of stable periodic behavior
(i.e., steady state).
Based on this equation, it would take 3.32 half-lives to reach
90% of the steady state concentration and 6.64 half-lives to reach
99%. Under the assumption that uptake into the brain is much
faster than clearance from brain, the approach-to-steady-state
equation was used to calculate the time it would take to reach 90%
of the steady state (Tss) and the concentration of PQ in brain (Css) at
Tss. The model was also used to estimate the maximum
concentration (Cmax) of PQ in whole blood, plasma and brain after
each daily dose of PQ, as well as the time needed to reach Cmax
(Tmax). The terminal half-life of clearance from the brain was
calculated as the duration of time in days for the brain
concentration to be reduced by 50% after the cessation of
treatment. An empirical method was also used to estimate theterminal steady state by estimating the rate of decline in the total
brain concentration of PQ after a single dose of 10 mg/kg.
2.7. Brain sample collection and microtomy for stereologic
investigation
Mice in Studies 4 and 5 designated for stereological investiga-
tions (Table 2) were deeply anaesthetized with sodium
pentobarbital, perfused with ﬁxative and brain tissues were
processed and evaluated according to the procedures described
in Supplementary Appendix 1.
2.8. Immunohistochemistry and counterstaining with cresyl violet
One in every 3rd brain section (40 mm thick) through the SNpc
were prepared for immunostaining using the standard avidin–
biotin complex (ABC) method (Study 4) or an immunoﬂuorescence
reactivity method (30 mm thick sections) (Study 5) as described in
Supplementary Appendix 1. In Study 4, a second set of sections was
stained with cresyl violet alone (CVO) to determine if the staining
method had an effect on the total neuron count.
2.9. Stereological assessment
Unbiased estimates of the total number of TH+ (DAB or Alexa
red labeled neurons), TH neurons (CV or DAPI-stained neurons
minus TH+ neurons) and total neurons (CVO or DAPI-stained
neurons) were calculated using the optical fractionator probe of
the Stereo Investigator software for design-based stereology,
image analysis, and 2-dimensional anatomical mapping, version
8.11 (MBF Bioscience, Williston, VT, USA) as described in
Supplementary Appendix 1. Stereological evaluation was per-
formed blinded to treatment group. The operator was unaware of
the treatment group to which individual mice belonged; the order
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randomized design. A needle track through one hemisphere
permitted the operator to distinguish the left hemisphere from the
right. Contours (virtual outlines) of the right and left SNpc were
drawn manually using the computer mouse for each montage
image. Contours were drawn around the SNpc in a manner
consistent with the description provided by Baquet et al. (2009).
Hence, contours were drawn to exclude the pars lateralis, pars
reticulata and the ventral tegmental region. Rostrally, the contour
of the SNpc began near the subthalamic nucleus, and it ultimately
extended to the caudal aspect of the retrorubral ﬁeld. The
boundary for the posterior medial SNpc was the medial lemniscus,
whereas the ventrolateral margin was indicated by the dorsal
portion of the pars reticulata. The ventral tegmental area (VTA)
deﬁned the anterior medial border of the SNpc, and densely
cellular populations of TH+ neurons were used to approximate the
mediodorsal extremity. The number of neurons in the right and the
left SNpc were summed to provide an estimate of the total number
of TH+ or TH neurons in the SNpc.
Guard zones were established to prevent miscounting of
neurons near the surface of the sections due to surface distortion
artifacts (Boyce et al., 2011). Neuronal cell bodies were counted
using the 100 oil microscope objective. A neuron was counted at
the point where the nuclear membrane was in sharp relief while
focusing up and down in the z-axis, and when the estimated center
of the nucleus was within the counting frame and contour lines
simultaneously, and also did not touch a red counting-frame line or
contour line in the xy-axis.
The criteria governing the identiﬁcation of neurons were
established a priori, as follows:
(1) TH+ neurons were identiﬁed by dense cytoplasmic immuno-
labeling (i.e., detected with the DAB chromogen which appears
as a dark brown reaction product within the neuron).
(2) In ﬂuorescent-labeled sections, TH+ neurons were identiﬁed by
dense cytoplasmic immunostaining identiﬁed with the Alexa
red ﬂuorophore.
(3) TH neurons were identiﬁed in DAB-labeled sections by deep
basophilic cytoplasmic CV staining of Nissl substance. THnuclei,
relative to other cell types such as glial cells, were generally
smaller, and TH neurons had dendritic or axonal processes.
(4) In CVO- and DAPI-stained sections, TH+ and TH neurons had
CV- or DAPI-stained nuclei of all cells in the section (e.g., TH+
neurons, TH neurons and glial cells). DAPI-stained neurons
(total neurons) were distinguished by their sizes, shapes and
nucleolus appearances.
For the ﬂuorescent-labeled sections, the number of TH neurons
in the SNpc was calculated by subtracting the number of TH+
neurons (Alexa red, immunolabeled neurons) from the total number
of neurons (DAPI-stained neurons). Neurons stained with TH+, TH,
CVO and DAPI (see Fig. S1 for a representative photomicrograph)
were tagged by applying virtual markers at the sites. Section
thickness (mm) was measured at each counting frame site, and these
measurements were averaged by the Stereo Investigator software to
determine the mean thickness per section. Estimation of the total
TH+ and TH cell numbers in the SNpc of each mouse brain was
performed by the software as described in Appendix 1.
To determine if the tissue processing method had an effect on
total neuron count, which was calculated as the sum of TH+
(chromogenic-labeled) and TH (CV-stained) neurons, a second set
of sections was stained with cresyl-violet-only (CVO) staining
(Study 4). In this case, the total number of neurons in the SNpc was
calculated based upon the number of CVO-stained neurons. In
Study 5, the total number of neurons was based upon the
stereological count of ﬂuorescent, DAPI-stained neurons; thenumber of TH neurons was calculated as the total number of
neurons minus the number of TH+ neurons.
Neuronal cell counts were recorded for each animal and other
relevant details of the stereological analyses (e.g., estimates of the
total area and volume of the SNpc). Additionally, the Stereo
Investigator software generated coefﬁcient of error (CE) values for
each of the total TH+ and TH cell counts. The CE was used to
determine if the number of neurons sampled stereologically was
sufﬁcient (i.e., CE < 0.1). At least one animal in the MPTP and/or
one animal in the vehicle control group was re-evaluated
periodically and blindly within the randomized block in order to
assess the intra-study variability of the stereological method.
Because there was an a priori hypothesis that PQ and MPTP would
reduce both the number of TH+ neurons in the SNpc and the contour
area and volume of the SNpc, a one-sided two-sample t-test
(Snedecor and Cochran, 1980) was performed on both TH+ and total
neuronal cell counts, as well as on contour volume. Statistical
comparisons of neuronal cell counts between the hemispheres and
across the depth of sections were two-sided, two sample t-tests.
2.10. Neuropathology
Time- and dose-intensive series of histopathological evaluations
were performed on brain samples collected in Studies 3, 4 and 6. In
Study 6, brains were collected from PQ and MPTP-treated mice from
4, 8, 16, 24, 48, 96 and 168 h after the last of 1, 2 or 3 doses of PQ (10,
15, or 25 mg/kg/doses), as well as after the last of 4 doses of MPTP
administered on a single day (Table 2). Perfused-ﬁxed brains from
the pathology subsets of animals in Studies 3, 4 and 6 were shipped
to Neuroscience Associates, Inc., for trimming, sectioning and
staining. A maximum of 25 brains were embedded in a gelatinous
matrix (Multibrain1) by Neuroscience Associates Inc. Twenty-ﬁve
brains were assigned to the matrix in a block-random fashion, so that
a block comprised of a vehicle control animal, an MPTP-treated
animal and an animal from each PQ-treated group.
The brain (caudate/putamen area) was sectioned in the
transverse plane from a level rostral to the striatum (caudate/
putamen) caudally through the caudal extent of the SNpc at section
thicknesses of 30 mm in the coronal plane. Seven serial sections
were obtained at 12-section (360 mm) intervals. This block of
tissue encompassed all of the structures deﬁned as basal ganglia
including the striatum, globus pallidus, SNpc, and subthalamic
nuclei. Tissues adjacent to the basal ganglia, and in the plane of the
section including the frontal cortex, hippocampus, VTA and rostral
pons, were assessed separately.
The sections were processed as follows:
1. Tyrosine hydroxylase, an enzyme involved in the synthesis of
DA, was immunohistochemically labeled (TH+) to identify
dopaminergic neurons and their neuronal processes (axons,
dendrites and synaptic terminals).
2. Glial ﬁbrillary acidic protein (GFAP) was immunohistochemi-
cally labeled to selectively identify protein ﬁlaments unique to
activated astrocytes.
3. Ionized Calcium Binding Adaptor Molecule 1 (IBA-1), a protein
expressed by activated microglia, was immunohistochemically
labeled to detect microglial cell activation.
4. Amino Cupric Silver (Am Cu Ag) is a cytochemical stain that
selectively stains the disintegrating elements of dead neuronal
cell bodies and the neuronal processes (axons, dendrites and
synaptic terminals). The dead cells/processes are labeled with
black particles (silver) against a pale background, permitting the
detection of single necrotic neurons.
5. Caspase 3 is an enzyme that is expressed by cells during
apoptotic cell death. The caspase 3 cleavage product was
immunochemically labeled to detect neurons that are in the
Fig. 2. Concentration of PQ in the forebrain (excluding the olfactory bulb) of male
C57BL/6J mice 7 days after the last ip injection of 10 or 15 mg/kg PQ (Study 4).
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sections were evaluated for caspase 3.
6. Thionine is a general morphological stain that detects Nissl
substance, thereby revealing nuclear details within a variety of
cell types.
7. Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) is a method for detecting DNA fragmentation. When
used in combination with cleaved caspase 3 immunoreactivity,
it provides a sensitive indicator of apoptosis. Only sections of the
SNpc were processed for TUNEL.
Slides for neuropathogical evaluation were prepared using
standard procedures developed by Neuroscience Associates
(http://www.neuroscienceassociates.com/stains.htm). The slides
were evaluated by the study pathologist at Tox Path Specialists
without knowledge of the treatment group (i.e., ‘‘blinded’’) being
evaluated. A qualitative scoring system was used to characterize
the severity of the occurrence of necrotic cells, indicated by
cellular uptake of amino cupric silver, the magnitude of the glial
(microglia, astrocyte) response to treatment, the loss of staining
for TH and an assessment of whether treatment triggered
apoptotic mechanisms (caspase 3 expression and DNA fragmen-
tation [TUNEL]) as described in Supplementary Appendix 1. An
open, ‘‘unblinded’’ peer review was conducted for Study 6 by a
second neuropathologist.
3. Results
PQ and MPTP solution concentrations were within 10% of
targeted concentrations in all studies, indicating that the intended
doses were administered.
3.1. PQ and MPTP tolerability
Three out of 5 mice died or were sacriﬁced moribund after being
administered the third of 3 doses of 35 mg PQ/kg (Study 1). These
animals displayed perivascular edema with mixed inﬂammatory
inﬁltrate in the lungs, endothelial hypertrophy of the pulmonary
vasculature, tubular degeneration in the kidneys and vacuolation
of the zona fasciculata of the adrenal gland.
There was no mortality in mice administered three doses of 10,
20, 25 or 30 mg PQ/kg. Clinical signs were minimal (hunched
posture) at PQ doses of 10, 20, 25 or 30 mg/kg. PQ-treated mice in
all groups displayed a dose-dependent reduction of food intake and
body weight loss at all doses, with the largest effect (approximate
2 g weight loss) noted after the third dose (Supplementary Fig. S2).
Effects were less pronounced at doses of 10 and 15 mg/kg/dose.
Only two out of 135 mice in these studies died when
administered MPTP at ip doses of 10 mg/kg/dose, 4 times a day,
2 h apart. The 133 surviving mice did not display any clinical signs
except for reduced food consumption and a transient reduction in
body weight gain (Supplementary Fig. S2).
3.2. Pharmacokinetics (Study 7)
PQ was rapidly absorbed after ip injection. The time elapsed
from injection to achieving peak blood and plasma concentrations
(Tmax) for the 10 mg PQ dose group ranged from 0.20 to 0.25 h (12–
15 min). The concentration of [14C] PQ quickly fell to below
background levels within 4–8 h (Fig. 1A). Peak concentrations of
[14C] PQ (Cmax) in whole blood and plasma tended to remain
constant with each of the 3 successive doses (data not shown). Cmax
values calculated for whole blood and plasma were 0.070 and
138 mM [14C] PQ, respectively, in the 10 mg PQ/kg dose group. Cmax
calculated for the 1 mg/kg dose group was approximately 10-fold
lower.The mean concentration of [14C] PQ in the brain was similar at
all time-points for the forebrain, midbrain and cerebellum and
approximately 2-fold higher in the olfactory bulb (Fig. 1B and C)
when compared to the rest of the brain. The Tmax calculated for the
brain (0.25 h) was only slightly longer than that calculated for
plasma (0.2 h), indicating that PQ partitioned rapidly from blood to
the brain. The concentration of PQ in the brain of animals that had
been perfused by cardiac puncture, 90 and 240 min after dosing,
were comparable to the brain concentrations in mice that had not
been perfused (data not shown), suggesting that the [14C] PQ found
in the brain was not due to [14C] PQ located in the brain’s blood
vessels.
The PBPK-modeled concentration of [14C] PQ in the brain
increased progressively with each successive dose of 10 mg PQ/
dose based upon data from Study 7 (Fig. 1D). The duration of time
(Tss) needed to reach 90% of the steady state was 80 days. The
concentration (Css) in whole brain at Tss was 2.8 mM [
14C] PQ
(Fig. 1D). Css represented approximately 0.3% of the total daily dose
of 10 mg/kg. The terminal half-life of elimination of PQ from the
brain was 24 days, as determined by empirically ﬁtting the data for
PQ clearance from the brain after a single dose (Fig. 1C), or 22.5
days based upon modeling (Fig. 1D). A comparison of the Cmax
predicted by the PBPK model to an empirical ﬁt of the data from the
C57BL/6J mice treated with PQ indicated that the model over-
estimated the empirical data by approximately 2-fold.
The mean PQ concentration measured in the brain 7 days after
the administration of PQ (Study 4) was dependent primarily on the
total dose administered (Fig. 2). When the total dose administered
was equivalent (i.e., 10 mg PQ/kg  3 vs. 15 mg PQ/kg  2), the PQ
brain concentration was marginally greater when the dose was
administered over 2 weeks (i.e., 15  2) than when it was
administered over 3 weeks, indicating that although only a small
fraction of the dose is taken up by the brain, it was slowly
eliminated. Measured PQ concentration in the brain approximated
the PBPK-estimate of [14C] PQ (Fig. 2), although the model-
predicted brain concentration of [14C] PQ 7 days after the last dose
was 1.6-fold greater than the measured PQ concentration (Fig. 2).
3.3. Neurotransmitter concentration in the striatum (Studies 2, 3 and
5)
PQ, administered by the ip route at doses up to 25 mg/kg once a
week for 3 weeks, had no consistent effect on the striatal
concentration of DA, DOPAC or HVA, or on DA turnover (Studies
2, 3 and 5), as assessed 7 days after the last dose relative to the
Fig. 3. Striatal dopamine, DOPAC, HVA concentration and dopamine turnover
(percent of control mean) for C57BL/6J mice administered either PQ or MPTP.
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at a dose of 10 mg/kg/dose administered 4 times in a single day,
signiﬁcantly suppressed DA (75–90%), DOPAC (60–80%) and
HVA (45–70%) levels, and signiﬁcantly increased DA turnover
(130–180%) with respect to the control group (Fig. 3).
3.4. Stereology (Studies 4 and 5)
In Study 4, there was a statistically signiﬁcant reduction in both
the mean number of TH+ neurons (p = 0.001) and in the mean
number of TH+ plus TH counter-stained CV neurons (p < 0.023) in
mice that received 15 mg PQ/kg/dose  3 doses, however, there
was no effect of PQ on the total number of CVO-stained neurons
(p = 0.342) in these mice (Fig. 4). There was no effect of PQ on the
number of TH+ neurons or the mean total number of CVO neurons
in groups of mice administered either SYN PQ or SIG PQ at a dose of
10 mg PQ/kg/dose for 3 doses (Groups 2 and 6), or in groups of mice
given 15 mg SYN PQ/kg/dose for either 1 (Group 5) or 2 (Group 4)
doses.
In Study 5, there were no statistically signiﬁcant effects of PQ
administration on either chromogenic or ﬂuorescent-labeled TH+
neuronal cell counts (Fig. 5). The mean number of TH+ neurons,
however, trended downward, with progressively lower valuesFig. 4. Number of TH+ (chromogenic-labeled neurons), TH (CVO-stained neurons)
and the total number of neurons (chromogenic-labeled + CVO-stained neurons)
(Mean  SEM) in the SNpc of male, C57BL/6J mice 7 days after the last ip injection of
either PQ or MPTP (Study 4).obtained in the 3  15 and 3  25 mg/kg dose groups when
compared to the 3  10 mg/kg dose group, for both chromogenic-
and ﬂuorescent-stained sections. There was no effect of PQ
treatment on the mean total number of neurons assessed, in
either CVO-stained sections or DAPI-labeled sections.
The mean number of DAB-labeled, TH+ neurons was signiﬁ-
cantly reduced (p < 0.05) in the MPTP-treated group in Study 4, but
the mean total number of CVO neurons in the SNpc was not
signiﬁcantly reduced (Fig. 4). The mean number of ﬂuorescent-
labeled (Alexa red) TH+ neurons was reduced (p < 0.05) in the
MPTP group, whereas the mean number of DAB-labeled TH+
neurons was reduced, but not signiﬁcantly (p = 0.06; Fig. 5). The
mean total number of neurons in the MPTP-treated groups (Study
4) was not signiﬁcantly reduced when assessed using CVO-only
staining (p = 0.1; Fig. 4) or DAPI staining (p = 0.08; Fig. 5; Study 5).
The mean cross-sectional area of the contours drawn blinded to
dose group, and the calculated mean SNpc volume were
signiﬁcantly reduced in the MPTP-treated DAB-labeled sections,
but not in Alexa red-labeled sections (Fig. 5; Study 5). Mean
contour area and SNpc volume were also signiﬁcantly reduced in
the 15 mg PQ/kg  3 dose group and the 25 mg PQ  3 dose group
for the DAB-labeled sections, but not for the ﬂuorescent-labeled
sections. There was no effect of PQ on mean contour area in the
10 mg PQ/kg  3 dose group. There were no effects of PQ-
treatment on SNpc contour area or volume in Study 4 (data not
shown).
There were no signiﬁcant differences between the left and right
SNpc in the number of TH+ neurons, TH neurons or the total
number of neurons (Study 5 – data not shown). However, there
were signiﬁcant differences in neuronal counts through the depth
of the thick section. These differences were more pronounced in
the DAB-labeled than in the ﬂuorescent-labeled sections (Supple-
mentary Fig. S3).
Stain penetration artifact was not evident for either the CVO- or
DAPI-labeled neurons (Fig. S3), although there were clear
differences in cell density through the depth of DAB-labeled
sections. The number of TH+ Alexa red labeled neurons in the
control group was approximately 66% greater than the mean
number of TH+ neurons determined by DAB labeling.
3.5. Neuropathology (Studies 3, 4 and 6)
PQ doses of 10, 15 or 25 mg/kg administered 1, 2 or 3 times,
with each dose separated by 7 days (Studies 3, 4 and 6), did not
induce neurodegenerative changes (degeneration or disintegra-
tion of neurons or neuronal processes including disintegrating
synaptic terminals) in the SNpc or the striatum, as indicated by
the absence of an increase in cupric silver staining (Supplemen-
tary Figs. S4 and S7; Photomicrographs: S10 and S11). The
intensity of TH+ immunoreactivity  in PQ-treated animals was
comparable to the controls (Supplementary Figs. S4 and S7;
Photomicrographs: S16 and S17). There was no evidence of either
increased labeling of the caspase 3 cleavage product or increased
TUNEL in PQ-treated groups (data provided in Supplementary
Table S2), indicating that apoptotic cell death was not triggered
by the ip injection of PQ. Microglial cells and astrocytes were not
activated by PQ treatment 4, 8, 16, 24, 48, 96 or 168 h after the last
dose (Supplementary Figs. S5 and S8; Photomicrographs: S14 and
S15), indicating that cell necrosis and cell death processes were
not induced by PQ treatment. There was no evidence of neuronal
cell death or microglial or astrocytic activation in the cerebral
cortex, striatum, thalamus/hypothalamus, midbrain, SNpc, VTA
or the pons (rostral hindbrain) based upon evaluations of brain
sections that spanned the area from the striatum to the caudal
midbrain. Numerical grading scores for Study 6 are presented in
Supplementary Table S2.
Fig. 5. Number of TH+ (chromogenic- or ﬂuorescent-stained neurons), TH (CVO-stained neurons) and total neurons (chromogenic- or ﬂuorescent-labeled neurons + CVO-
stained neurons) (Mean  SEM) in the SNpc of male, C57BL/6J mice 7 days after the last ip injection of either PQ or MPTP (Study 5).
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tegrating neurons in the SNpc and degenerating neuronal
processes (synaptic terminals) in the striatum, as indicated by
the uptake of cupric silver stain (Figs. S4, S6, S7, and S9; see Fig. 6
for representative photomicrographs). A qualitative reduction in
the intensity of TH labeling was present in the SNpc, but this was
more pronounced in the striatum. There was no evidence of
increased TUNEL or caspase 3 cleavage products in MPTP-treated
mice, suggesting that MPTP-induced cell death in the SNpc was not
mediated by apoptosis (Supplementary Table S2).
Accompanying the MPTP-induced neuronal degeneration were
pronounced activation of microglia (IBA-1 immunoreactivity) and
astrocytes (GFAP immunoreactivity) in the striatum, as well as
moderate activation in the SNpc (Figs. S5, S6, S8, and S9; Fig. 6
displays representative photomicrographs of IBA-1 and GFAP
staining in MPTP-treated mice). A plot of the time course of
neurodegeneration and glial activation in MPTP-treated mice
indicated that the intensity of neuronal degeneration increasedearlier than either the reduction in TH+ labeling or microglial and
astrocyte activation (Figs. S6 and S9). In the striatum, all four
processes peaked within 48 h of the last dose, but astrocyte
activation persisted with greater severity in the striatum up to
168 h. In the SNpc, neuronal degeneration and glial responses were
no longer detectable by 168 h post-treatment (Fig. S6).
4. Discussion
4.1. Pharmacokinetic studies
The pharmacokinetics of [14C] PQ in the blood, plasma and brain
following ip administration to C57BL/6J mice showed that [14C] PQ
was rapidly taken up after ip injection and that tissue concentra-
tion was linearly related to the dose. The initial half-life (rapid
phase) of elimination from blood and plasma was short (17 and
18 min for the 1 and 10 mg PQ/kg doses respectively, calculated
from the ﬁrst hour of data). The concentration of [14C] PQ in brain
Fig. 6. Uptake of silver stain in degenerating neuronal processes in the striatum of a MPTP-treated mouse compared to a control (panel A); Decreased tyrosine hydroxylase
staining in the striatum (panel B), increased staining for microglia (panel C) and astrocytes (panel D).
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from the brain was slow, with the terminal half-life estimated to be
either 24 days, based on an empirical ﬁt of the brain clearance data,
or 22.5 days based on the PBPK model. The estimated terminal
half-life is slightly shorter than that reported by others (28 days in
Prasad et al., 2007 and 1 month in Prasad et al., 2009). The brain
concentration of PQ increased with repeated PQ dosing (Fig. 1B),
but the rate of elimination from the brain was independent of the
number of doses administered.
The precise cellular localization of [14C] PQ in the brain, as
evaluated either by autoradiography (data not shown), or by
radiometric counts in subsections of the brain, could not be
determined in these experiments. However, approximately
equal concentrations of [14C] PQ were observed in all regions
of the brain examined except for the olfactory bulb, which had an
approximately 2-fold greater concentration (Fig. 1C). Previous
work has demonstrated that PQ does not selectively accumulate
in any speciﬁc region within the SNpc or the striatum of the rat,
although the concentration of [14C] PQ was greater in the
olfactory bulb and pineal gland, including the lining of the lateral
ventricle, the fourth ventricle, the area postrema and the
hypothalamus, as compared to the rest of the brain (Naylor
et al., 1995; Widdowson et al., 1996). In the rhesus monkey, PET
imaging of [11C] PQ indicated that PQ uptake into the brain was
minimal and consistent, and dependent on the volume of blood
distribution to substructures within the brain. The pineal gland
and lateral ventricles were the only structures which showed
evidence of signiﬁcant PQ uptake (Bartlett et al., 2009). Overall,
the pattern of PQ distribution in the brain is similar across
species, with higher concentrations being found in areas of the
brain not fully protected by the blood–brain barrier. These
results are inconsistent with the proposal that monovalent PQ is
taken up into dopaminergic neurons by the DAT transporter
(Rappold et al., 2011).Although PQ was slowly eliminated from brain, it is unknown
whether PQ is bound to tissues or organelles within the brain, or
whether speciﬁc neurons or other cells selectively retain PQ. It is
also unknown whether PQ undergoes redox cycling in the intact
brain to generate superoxide anions, as has been described for the
lung (Bus et al., 1976; Smith, 1985). However, evidence of free
radical production has been observed in neuronal cell cultures.
Peng et al. (2004) reported that immortalized dopaminergic
neurons (N27 cell line) exposed in vitro to 400 mM PQ for 18 h
displayed an increased amount of the caspase 3 cleavage product.
The authors suggested that the 50% reduction in viability after 24 h
was in part due to an apoptotic mechanism triggered by increased
free radical production, even though superoxide anion was not
directly measured. Gonzalez-Polo et al. (2004) reported a 70%
reduction in cerebellar granule cells’ viability when exposed in
vitro to 5 mM PQ for 24 h.
The PBPK model predicted that Css  2.8 mM PQ in the brain
after repeated daily ip dose of 10 mg PQ/day. This concentration
was 30- to 60-fold lower than the concentration that resulted in a
10% reduction in cell viability in the study by Peng et al. (2004),
although it was similar to the concentration evaluated by
Gonzalez-Polo et al. (2004). However, there was no evidence of
either cellular necrosis or apoptotic cell death in mice adminis-
tered high doses of PQ in the current investigation. These results
are contrary to both the in vitro and the in vivo work reported by
Peng et al. (2004). Based upon the pharmacokinetic data, it is
unlikely that PQ exposure in the in vitro studies reﬂect the
conditions of PQ exposure of the brain following systemic (ip)
administration to C57BL/6J mice.
4.2. Neurochemistry
In contrast to the reports of reduced DA levels (Kang et al.,
2009) and/or increased DA turnover in the striatum following PQ
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show that weekly administration of PQ to C57BL/6J mice for 3
weeks at doses up to the maximum-tolerated dose had no effect.
PQ doses up to 25 mg/kg administered by ip injection on 3 weekly
occasions did not alter either striatal DA, DOPAC and HVA or the
turnover of dopamine in three studies. In contrast, MPTP
signiﬁcantly reduced the level of dopamine and its metabolites
and increased DA turnover, which is consistent with the known
effects of MPTP (Heikkila et al., 1984a,b).
Researchers who have observed reductions in the number of
TH+ immunoreactive neurons in the SNpc without ﬁnding changes
in striatal DA levels have suggested that the surviving SNpc
neurons undergo a compensatory up-regulation of DA synthesis
(McCormack et al., 2002). In our experiments, however, there was
no evidence of dopaminergic neuronal cell death in the SNpc nor
was DA turnover increased in the striatum. The most parsimonious
interpretation of these results is that in PQ-treated mice,
compensation of neurotransmitter synthesis in the striatum is
not triggered because dopaminergic neurons in the SNpc have not
died.
It is possible that repeated daily dosing of PQ for 24 days might
reduce striatal DA concentrations without changing DA turnover as
reported by Prasad et al. (2009). However, preliminary results
from an ongoing study, in which PQ was administered in the diet of
C57BL/6J mice for 13 weeks at doses of 14–22 mg/kg/day in males
and females, respectively, indicate that neither striatal DA levels
nor dopamine turnover were affected.
4.3. Stereological assessment of the number of dopaminergic neurons
in the SNpc
Several authors have previously reported that ip administra-
tion of PQ to C57BL/6J male mice reduced the number of TH+
dopaminergic neurons in the SNpc (Brooks et al., 1999;
Thiruchelvam et al., 2000; McCormack et al., 2002; Peng et al.,
2004; Jiao et al., 2012; Gollamudi et al., 2012). In our study, there
was no consistent, statistically signiﬁcant, stereological evidence
of a loss of DAB-labeled TH+ neurons in the SNpc following PQ
treatment (Fig. 4). Although a statistically signiﬁcant reduction in
the number of TH+ neurons was observed in the 15 mg PQ/kg  3
dose group, 7 days after the last dose in Study 4, the total number
of CVO-stained neurons in the SNpc was unaffected by treatment.
Similarly, the total number of neurons, assessed using CVO or
DAPI in Study 5, was also unaffected by PQ treatment. These
results suggest that under some conditions, dopaminergic
neurons may undergo a phenotypic reduction in TH expression
following PQ treatment. Alternatively, PQ may have interfered
with the epitope involved with the immune recognition of TH+
neurons in situ.
The stereological ﬁnding of a reduced number of TH+ neurons
observed in Study 4 was not replicated in Study 5. Study 5 was
more comprehensive than Study 4 because both DAB-labeled and
Alexa red ﬂuorescent-labeled TH+ neurons were evaluated after 3
weekly doses of 10, 15 or 25 mg PQ/kg. Although the number of
DAB labeled TH+ neurons in the 15 and 25 mg PQ groups tended to
be reduced compared to the control group (Fig. 5), this may have
been due to the slightly, yet statistically signiﬁcantly decreased
contour areas and volumes for the 15 and 25 mg PQ-treated
groups. This could occur if the intensity of TH+ immunoreactivity
was reduced in the high-dose PQ-treated groups, thereby making it
more difﬁcult to discern the precise margins of the SNpc. Mitra et
al. (2011) reported a diminution in TH expression in the SNpc,
hippocampus and frontal cortex in Swiss Webster mice given ip
injections of 10 mg/kg PQ twice weekly for 4 weeks and a
decreased number of TH+ neurons in the SNpc of these mice; the
effect was more pronounced in the 10 mg/kg group compared tomice administered lower (5 mg/kg) or higher (20, 40 or 80 mg/kg)
of PQ.
The results from Studies 4 and 5 are inconsistent with those
reported in older studies that used a similar dosing regimen
(Brooks et al., 1999; Thiruchelvam et al., 2000; McCormack et al.,
2002) and with more recent studies where PQ was administered
more frequently by ip injection (Peng et al., 2004; Jiao et al., 2012)
or continuously via an Alzmet pump (Gollamudi et al., 2012). The
reasons for these discrepancies remain unclear. It is possible that in
the more recent studies, the frequency of PQ administration may
have resulted in different brain concentration kinetic proﬁles.
However, it is unlikely that either ip injection or continuous
subcutaneous administration of PQ is representative of potential
human exposure encountered in the agricultural use of PQ (Lock
and Wilks, 2001).
In Study 5, there were approximately 66% more TH+ neurons in
the SNpc in ﬂuorescent-labeled compared to chromogenic-labeled
sections (10,000 neurons; Fig. 5), conﬁrming the results of Prasad
and Richﬁeld (2010). This difference may in part reﬂect the greater
penetration of ﬂuorescent dye, as well as the greater ease of
identifying TH+ neurons with ﬂuorescent labeling because of
reduced shrinkage of the sections when aqueous mounts were
employed for the ﬂuorescent labeling method, compared to the air-
dried mounting technique used for the DAB prepared sections.
Although it has been reported that the absolute number of TH+
neurons in the C57BL/6J male mice is 8300, based upon an
evaluation of 10 mm parafﬁn-embedded serial sections throughout
the entire SNpc (Baquet et al., 2009), it is likely that the variability
in the number of TH+ neurons between laboratories is attributed to
different criteria used by investigators to draw contours around
the SNpc and differences in the quality of immunochemical
labeling of TH+ neurons.
In Study 5, the mean number of DAB-immunostained TH+
neurons in the vehicle control C57BL/6J male mice (Mean = 9988;
SEM = 584; N = 8) was fever than some researchers have reported
for DAB-immunostained TH+ neurons (McCormack et al., 2002;
Mean = 12,321; SEM = 118; N  5) and greater than others as
determined by serial reconstruction (Baquet et al., 2009;
Mean = 8305; SEM = 539; N = 4) or using the optical fractionator
(Baquet et al., 2009; Mean = 8716; SEM = 338; N = 10). It is likely
that the serial reconstruction method of Baquet et al. (2009)
provides the most accurate estimate of the number of TH+ neurons
in the SNpc.
Variability, as represented by the coefﬁcient of variation (CV) in
the number of DAB immunostained TH+ neurons in Study 5
(CV = 0.165) was comparable to the variability reported by Baquet
et al. (2009) based on serial reconstruction (CV = 0.130) or the
optical fractionation method (CV = 0.123) and was much greater
than the variability reported by McCormack et al. (2002;
CV  0.021). The reason for the greater precision in the McCormack
et al. (2002) study compared to Baquet et al. (2009) and the
present investigation is unknown. Prasad and Richﬁeld (2008),
however, using a ﬂuorescent method for detecting TH+ neurons in
the SNpc of male C57BL/6J, presented data indicating that 55 to
73% of untreated mice obtained from 5 different suppliers had
abnormally low TH+ staining and that these mice had on average
32% fewer TH+ neurons than did ‘‘normal’’ TH+ staining mice. Part
of this variation was apparently due to inter-hemispheric
differences, which Prasad and Richﬁeld (2010) cautioned could
confound the interpretation of stereology studies.
Furthermore, while few investigators have reported cell counts
through the depth of sections, our results indicate that DAB-
labeled sections are considerably more variable in TH+ cell counts
through z-depth than were TH+ cell counts, based upon ﬂuores-
cent-labeled TH+ neurons (Alexa red) or DAPI-stained dopaminer-
gic neurons. While varying cell count through the depth of section
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demonstration that there was no differential effect of PQ or MPTP
treatment on this proﬁle (Fig. S3) suggests that a relative effect of
treatment would be detectable. This was conﬁrmed by the results
from the low-dose (10 mg/kg/dose  4 doses) MPTP-treated group,
where either a statistically signiﬁcant or borderline statistically
signiﬁcant reduction in the number of TH+ neurons was noted in
the SNpc. Although some investigators have recommended that
larger doses of MPTP be used (Jackson-Lewis and Przedborski,
2007), the low-dose regimen (four doses of 10 mg MPTP/kg
administered 2 h apart) used in these experiments was deliber-
ately employed to determine if the stereological methods would be
sensitive enough to detect relatively small changes in the number
of TH+ neurons in the SNpc. The SEMs calculated for control groups
using chromogenic-stained TH+ neurons (SEM = 584) and Alexa
red labeled TH+ neurons (SEM = 1305) are greater than some
researchers have reported (McCormack et al., 2002), but are in
agreement with others (Jiao et al., 2012).
Using a relatively low dose of MPTP (10 mg/kg/dose  4 doses
2 h apart), a reduction in DAB-labeled neurons (p = 0.017; Study 4
or p = 0.06; Study 5) or a statistically signiﬁcant loss of Alexa red-
labeled TH+ neurons (p = 0.05; Study 5) was observed. There was
clear evidence that this dose of MPTP resulted in the necrosis of
dopaminergic neurons in the SNpc (Fig. S6), the activation of
microglia, the activation of astrocytes and the depression of striatal
DA concentration, with a corresponding increase in DA turnover
(Fig. 3). Thus the failure to achieve a statistically signiﬁcant loss in
the number of DAB labeled TH+ neurons in Study 4 was almost
certainly due to a combination of using a relatively low dose of
MPTP and high inter-animal variability in the number of TH+
neurons (Figs. 4 and 5), leading to relatively large SEMs.
4.4. Neuropathological assessment of neuronal cell death in the SNpc
and striatum
Histopathological changes were evaluated in the striatum,
midbrain SNpc and rostral pons of C57BL/6J mice 4, 8, 16, 24, 48, 96
and 168 h after the last of 1, 2 or 3 doses of paraquat or MPTP
treatment by a pathologist who was ‘blinded’ to the treatment
groups of the individual animals. The pathologist identiﬁed every
mouse that had been treated with MPTP based on clear evidence of
cell damage/death, as indicated by amino cupric silver staining
(Figs. S6 and S9), as well as by activation of microglia and
astrocytes (Figs. S5 and S8). The pathological changes began in the
striatum within 4 h of MPTP administration (Fig. S6). The effect of
MPTP on the SNpc commenced within 8 h of dosing and returned
to baseline within 4 days, although astrocytes remained activated
for up to 7 days post-dosing (Fig. S6). There was no effect of PQ on
any pathological endpoint in the striatum or SNpc at any time after
1, 2 or 3 doses of 10, 15 or 25 mg PQ.
There was no evidence of cell death in structures adjacent to
the striatum, and the SNpc including the VTA, thalamic nuclei,
hypothalamus, hippocampus and rostral pons, as indicated by
no increase in the silver staining of neurons, indicators of
apoptosis or evidence of glial or astrocytic activation based on
blinded histopathological assessment of these structures. These
results are in contrast to the work by Mitra et al. (2011), who
reported evidence of a neuro-inﬂammatory response in the SNpc
and hippocampus of PQ-treated Swiss Webster mice. Purisai et
al. (2007) also reported increased counts of Mac-1 immunos-
tained neurons in the SNpc of C57BL/6J mice 1, 2, 4 and 7 days
after a single ip dose of 10 mg/kg PQ. The reasons for the
differences between the work of Mitra et al. (2011), Purisai et
al. (2007), and the present investigations is not known, although
different staining and evaluation methods were used in each
study.5. Conclusions
When PQ was administered by ip injection to C57BL/6J mice,
0.3% of the dose entered the brain and it was then slowly
eliminated. It is unknown whether PQ enters the neuron or if it
undergoes reduction-oxidation cycling. However, PQ did not cause
pathological or neurochemical changes in the brain when given in
doses up to and including 3  25 mg PQ/kg.
These studies did not consistently detect a signiﬁcant loss of
TH+-stained neurons of PQ-treated mice, as reported by others, nor
was there any evidence of neuronal cell death in the SNpc, nor any
effect on neurotransmitter levels in the striatum. However, the
effect of PQ on the number of TH+ neurons in the SNpc reported in
the published literature cannot be dismissed. If PQ has an adverse
effect in the brain of the C57BL/6J mice, it may be conﬁned to
reduced phenotypic expression of TH in dopaminergic neurons,
which would explain the absence of pathology or any effect of PQ
on DA turnover in the striatum. Reduced TH expression might also
explain the statistically signiﬁcant reduction in contour volume
observed following dosing with MPTP or PQ since the construction
of the contour is based, at least in part, on the immunolabeling of
TH+ neurons. What is clear is that the use of PQ to provoke a
statistically signiﬁcant reduction in TH+ neurons in the SNpc of the
mouse brain is a more fragile process than is currently character-
ized in the published literature. Additional studies are required to
resolve the differences between our results and those reported by
others, including the in vivo studies by Peng et al. (2004) and Jiao
et al. (2012).
It is possible that the stereological methods used in our studies
were inadequate to detect a PQ-induced reduction in the number
of dopaminergic neurons reported by others. However, the totality
of the evidence from this research program indicates there was no
consistent stereological evidence of a loss of TH+ staining in the
SNpc of male C57BL/6J mice administered PQ at near-lethal doses.
Neurochemical changes were always observed following MPTP
treatment, but there were never any changes in DA levels or DA
turnover in the striatum after PQ treatment. There was clear
evidence of neuropathological changes in the SNpc and the
striatum after MPTP treatment in three separate studies, but there
was no evidence that PQ had any effect on a broad range of
indicators of cell death, in both the SNpc and the striatum.
An important insight from this investigation was that the
‘‘blinded’’ neuropathological evaluation of the mouse brain was
able to segregate with 100% accuracy the MPTP-treated mice from
the control or PQ-treated animals. However, stereological assess-
ment could only statistically separate the MPTP-treated mice from
controls in two out of three studies. It is recognized that this may
be a consequence of the variability in the stereological results, but
the variation in these experiments was not markedly different
from the results obtained by others who have conducted similar
studies. This suggests that an unbiased assessment of neuronal cell
loss in the SNpc must include carefully conducted pathological
studies where the pathologist is ‘‘blinded’’ to the treatment of each
experimental animal.
In conclusion, the use of stereology, pathology and brain
neurochemistry may prove to be the appropriate combination of
endpoints for determining whether neurons in the SNpc of treated
mice are damaged following PQ treatment. If neurons in the SNpc
died as a result of treatment, one would expect that there would be
(1) a reduction in TH+ neurons and a proportional reduction in total
neuron count in the SNpc as determined by stereology; (2)
evidence of cell death within the SNpc based upon pathological
endpoints and (3) a reduction in DA levels and increased DA
turnover in the striatum. This is precisely the constellation of
effects seen following MPTP administration, but not after near-
lethal doses of PQ.
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